@habittrade

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY. · Analyst brief as of 2026-10-18.

The author highlights cancer-vaccine catalysts for MRK and MRNA alongside recent stock and ETF performance leaders; no holdings or directional trades are disclosed. The distinctive emphasis is biotech catalysts combined with performance screening, without an explicit consensus comparison. The final post reports TSLA's Roadster unveiling and targeted 2028 production, without establishing a change in positioning.

No positions disclosed this window — everything below is commentary, not book talk.

Coverage is mildly bullish and concentrated in retrospective performance screens, which account for eight of eleven signals. MRNA is the only repeated ticker, connecting biotech catalysts with weekly stock leadership; there are no disclosed adds, trims, exits, or explicit conviction shifts. The isolated TSLA product report does not establish a sustained theme, and the sparse window does not establish a conviction trajectory.

Alignment separates skin-in-the-game from commentary: ✓ = the author discloses a position consistent with their talk; “call (no pos)” = directional call without a disclosed position; “commentary” = opinion only.

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.